Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Not listed Phase 1 Interventional Accepts healthy volunteers

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

NCT05894902
Conditions
Major Depression, Post Traumatic Stress Disorder
Interventions
SM-001
Drug
Lead sponsor
Advanced Integrative Medical Science Institute
Other
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Phase 2 Interventional Results available

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595
Conditions
Depressive Symptoms, Anxiety, Cancer
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use
Interventions
0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

NCT07693257
Conditions
Healthy Participants Study
Interventions
N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg)
Drug
Lead sponsor
Jon Dean
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Generalized Anxiety Disorder
Interventions
CYB004, Psychotherapy
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Hollywood, Florida • Miami Lakes, Florida • Atlanta, Georgia + 3 more
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California